Åsa Kornfeld
Direttore/Membro del Consiglio presso ARCEDE PHARMA AB
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Bert Roland Kari Junno | M | 58 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 anni |
Michael Robin Witt | M | - | 10 anni | |
Johan Lindh | M | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 anni |
Knut Mikael Ingolf Lindstam | M | 58 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 anni |
Alexander Lidmejer | M | 43 | 14 anni | |
Christine Natasha Ryan | M | - | - | |
Theresa Comiskey Olsen | F | 61 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Luiza Jedlina | M | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 10 anni |
Kathrine Elisabeth Andreassen | F | 58 | 6 anni | |
Stefan Rehnmark | M | - | - | |
Mia Sandberg Lundblad | M | 50 | 2 anni | |
Annika Kollén | F | - | 3 anni | |
Suzanne Kilany | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Kristofer Svensson | M | - | - | |
Laurent Pacheco | M | 48 | 2 anni | |
Ingela Hallberg | M | 69 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 anni |
Anders Lönnberg | M | - | 3 anni | |
Maria Ekblad | F | - |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 2 anni |
Ulla Cristina Glad | M | 72 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | 8 anni |
Ola Skanung | M | 60 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Astrid T. Bratvedt | F | - | 5 anni | |
Jan Nilsson | M | 56 |
Aptahem AB
Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden. | - |
Johanna Asklin | M | 47 | 2 anni | |
Lars Hjarrand | M | 51 | 5 anni | |
Jostein Davidsen | M | 65 | 7 anni | |
Erik Magnusson | M | 63 | - | |
Terje Bakken | M | 58 | 6 anni | |
Narve Reiten | M | 63 | - | |
Ole Henrik Eriksen | M | 65 | 5 anni | |
Gustav Ingemar Kihlström | M | 71 | - | |
Edmée Steenken | F | - | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Svezia | 21 | 67.74% |
Norvegia | 10 | 32.26% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Åsa Kornfeld
- Contatti personali